



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

## ASX ANNOUNCEMENT

### **Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next-Generation Portfolio Approach**

Melbourne (Australia) and Indianapolis, IN (U.S.) – April 28, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an investor webinar exploring the evolution of PSMA<sup>1</sup>-targeted radionuclide therapy and Telix’s differentiated, multi-product approach to treating prostate cancer across the disease continuum.

Dr. David N. Cade, Telix Group Chief Medical Officer will host a discussion with Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital in Sydney, exploring what makes an effective PSMA-targeted therapy.

Professor Emmett will showcase data from her OPTIMAL-PSMA<sup>2</sup> investigator-initiated trial of TLX597-Tx (<sup>177</sup>Lu-DOTA-PSMA), Telix’s novel second generation small molecule candidate being developed to facilitate patient access to lutetium therapy in select geographies.

The presentation will be followed by Q&A.

#### **Webinar date and time:**

**AEST:** Thursday April 30, 2026, 9:30 a.m.

**EDT:** Wednesday April 29, 2026, 7:30 p.m.

Participants can register for the webinar at the following link:

<https://s1.c-conf.com/diamondpass/10053985-675tre.html>

TLX597-Tx has not received a marketing authorization in any jurisdiction.

#### **About Telix Pharmaceuticals Limited**

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit [www.telixpharma.com](http://www.telixpharma.com) for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [LinkedIn](#), [X](#) and [Facebook](#).

#### **Telix Investor Relations (Global)**

Ms. Kyahn Williamson  
SVP Investor Relations and Corporate  
Communications  
[kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

#### **Telix Investor Relations (Australia)**

Ms. Charlene Jaw  
Associate Director Investor  
Relations  
[charlene.jaw@telixpharma.com](mailto:charlene.jaw@telixpharma.com)

#### **Telix Investor Relations (U.S.)**

Ms. Annie Kasparian  
Director Investor Relations and  
Corporate Communications  
[annie.kasparian@telixpharma.com](mailto:annie.kasparian@telixpharma.com)

<sup>1</sup> Prostate-specific membrane antigen.

<sup>2</sup> Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.

---

*This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.*

## Legal Notices

### *Cautionary Statement Regarding Forward-Looking Statements.*

*You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.*

*The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.*

*This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.*

*Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.*

*©2026 Telix Pharmaceuticals Limited. All rights reserved.*